RJV Stock Chart & Stats
€0.20
€0.02(6.30%)
At close: 4:00 PM EST
€0.20
€0.02(6.30%)
Day’s Range― - ―
52-Week Range€0.14 - €0.49
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€39.31M
Enterprise Value€102.25M
Total Cash (Recent Filing)€17.18M
Total Debt (Recent Filing)€5.46M
Price to Earnings (P/E)―
Beta0.79
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,768,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)2.37
Price to Sales (P/S)0.98
P/FCF Ratio22.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.48Price Target Upside138.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EBITDA GrowthHigher EBITDA and margin demonstrate improving operating leverage and cost discipline as revenue scales. If maintained, this gives SomnoMed greater capacity to fund product development, absorb regional pressure, and convert its established device business into more durable earnings.
Cash Generation And Balance SheetPositive operating cash flow alongside a net cash position strengthens financial flexibility and reduces dependence on external funding. This supports continued capacity investment and product development while providing a buffer against uneven regional demand and currency-related pressure.
Manufacturing ScaleExpanded capacity and faster production turnaround improve the company’s ability to serve international demand and support clinical channel relationships. These operational gains can enhance scalability and service reliability, reinforcing the economics of its custom-device model over time.
Bears Say
Persistent Net LossesDespite improved EBIT and EBITDA, SomnoMed remains loss-making at the net-income level and generates negative returns on shareholder capital. This limits evidence of fully sustainable profitability and leaves the business more exposed to cost, investment, and regional execution pressures.
European Reimbursement HeadwindsChanges to eligibility, reimbursement, and referral pathways can reduce patient access and make demand harder to rebuild than in a normal cyclical slowdown. Because Europe is the largest region, these structural pressures could constrain growth and require sustained commercial restructuring.
Connected Care Regulatory UncertaintyUncertainty around the remaining FDA work and commercialization timing makes the Connected Care roadmap less dependable as a future growth contributor. Delayed approval or unclear market rollout could defer expected product benefits and keep investment returns difficult to assess.
Somnomed Limited News
RJV FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest stock price was €0.14 and its highest was €0.49 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is €39.31M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,768,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in DE:RJV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.48%
12-Months-Change
Fundamentals
Return on Equity
-5.44%
Trailing 12-Months
Asset Growth
-2.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
RJV Company Deck
RJV Earnings Call
Q4 2026
0:00 / 0:00
RJV Stock 12 Month Forecast
Average Price Target
€0.48
▲(138.50% Upside)